These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16297807)

  • 1. Comparison of Novacor and HeartMate vented electric left ventricular assist devices in a single institution.
    Kalya AV; Tector AJ; Crouch JD; Downey FX; McDonald ML; Anderson AJ; Bartoszewski CJ; Hosenpud JD
    J Heart Lung Transplant; 2005 Nov; 24(11):1973-5. PubMed ID: 16297807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the type of ventricular assisted device influence survival, infection, and rejection rates following heart transplantation?
    Shuhaiber J; Hur K; Gibbons R
    J Card Surg; 2009; 24(3):250-5. PubMed ID: 19438776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy.
    Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA sensitization in ventricular assist device recipients: does type of device make a difference?
    Kumpati GS; Cook DJ; Blackstone EH; Rajeswaran J; Abdo AS; Young JB; Starling RC; Smedira NG; McCarthy PM
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1800-7. PubMed ID: 15173739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of device surface and biomaterials with immunologic sensitization after mechanical support.
    George I; Colley P; Russo MJ; Martens TP; Burke E; Oz MC; Deng MC; Mancini DM; Naka Y
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1372-9. PubMed ID: 18544389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions.
    Drakos SG; Stringham JC; Long JW; Gilbert EM; Fuller TC; Campbell BK; Horne BD; Hagan ME; Nelson KE; Lindblom JM; Meldrum PA; Carlson JF; Moore SA; Kfoury AG; Renlund DG
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1612-9. PubMed ID: 17532964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experience.
    Morgan JA; John R; Rao V; Weinberg AD; Lee BJ; Mazzeo PA; Flannery MR; Chen JM; Oz MC; Naka Y
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1309-16. PubMed ID: 15115987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heartmate II axial-flow left ventricular assist system: management, clinical review and personal experience.
    Loforte A; Montalto A; Ranocchi F; Casali G; Luzi G; Monica PL; Sbaraglia F; Polizzi V; Distefano G; Musumeci F
    J Cardiovasc Med (Hagerstown); 2009 Oct; 10(10):765-71. PubMed ID: 19465866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation.
    Grady KL; Meyer PM; Dressler D; Mattea A; Chillcott S; Loo A; White-Williams C; Todd B; Ormaza S; Kaan A; Costanzo MR; Piccione W
    Ann Thorac Surg; 2004 Apr; 77(4):1321-7. PubMed ID: 15063260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes.
    Joyce DL; Southard RE; Torre-Amione G; Noon GP; Land GA; Loebe M
    J Heart Lung Transplant; 2005 Dec; 24(12):2054-9. PubMed ID: 16364849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices.
    Patel ND; Weiss ES; Schaffer J; Ullrich SL; Rivard DC; Shah AS; Russell SD; Conte JV
    Ann Thorac Surg; 2008 Sep; 86(3):832-40; discussion 832-40. PubMed ID: 18721570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does continuous flow left ventricular assist device technology have a positive impact on outcome pretransplant and posttransplant?
    Klotz S; Stypmann J; Welp H; Schmid C; Drees G; Rukosujew A; Scheld HH
    Ann Thorac Surg; 2006 Nov; 82(5):1774-8. PubMed ID: 17062246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes are similar in pulsatile and nonpulsatile left ventricular assist device recipients.
    Feller ED; Sorensen EN; Haddad M; Pierson RN; Johnson FL; Brown JM; Griffith BP
    Ann Thorac Surg; 2007 Mar; 83(3):1082-8. PubMed ID: 17307463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device.
    Baran DA; Gass AL; Galin ID; Zucker MJ; Arroyo LH; Goldstein DJ; Prendergast T; Lubitz S; Courtney MC; Correa R; Chan M; Spielvogel D; Lansman SL
    J Heart Lung Transplant; 2005 Nov; 24(11):1886-90. PubMed ID: 16297796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
    Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novacor left ventricular assist system versus Heartmate vented electric left ventricular assist system as a long-term mechanical circulatory support device in bridging patients: a prospective study.
    El-Banayosy A; Arusoglu L; Kizner L; Tenderich G; Minami K; Inoue K; Körfer R
    J Thorac Cardiovasc Surg; 2000 Mar; 119(3):581-7. PubMed ID: 10694620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events in the use of HeartMate vented electric and Novacor left ventricular assist devices: comparing apples and oranges.
    Pasque MK; Rogers JG
    J Thorac Cardiovasc Surg; 2002 Dec; 124(6):1063-7. PubMed ID: 12447167
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year.
    Martin J; Friesewinkel O; Benk C; Sorg S; Schultz S; Beyersdorf F
    J Heart Lung Transplant; 2006 Apr; 25(4):384-90. PubMed ID: 16563965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.